1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Adaptimmune Therapeutics PLC (ADAP)
  7. Quote

ADAP ADAP

Adaptimmune Therapeutics Share Price

4.07
-0.21 (-4.91%)
Upgrade to Real-Time
Afterhours (Closed)
4.07
Volume 321,653
Bid Price 4.10
Ask Price 5.50
News -
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Adaptimmune Therapeutics PLC ADAP NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
-0.21 -4.91% 4.07 00:00:01
Open Price Low Price High Price Close Price Prev Close
4.14 4.02 4.215 4.07 4.28
Trades Volume VWAP Dollar Volume Avg Volume
2,027 321,653  4.11  1,322,896 -
Last Trade Time Type Quantity Stock Price Currency
16:15:08 formt 100  4.10 USD

Period:

Draw Mode:

Adaptimmune Therapeutics PLC Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 635.75M 156.20M 125.08M  3.96M  - -0.96 -4.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
-  - - -5.72k 3.30%

more financials information »

News Adaptimmune Therapeutics

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

ADAP Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year0.000.000.000.0000.000.0%
3 Years0.000.000.000.0000.000.0%
5 Years0.000.000.000.0000.000.0%

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, NON-SMALL CELL LUNG CANCER, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.


Your Recent History
NASDAQ
ADAP
Adaptimmun..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.